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Abstract
Carbapenem-resistant Enterobacteriaceae (CRE) are emerging extremely drug-resistant pathogens; blaKPC is the predominant carbape-
nemase in Israel. Early detection of asymptomatic rectal carriers is important for infection control purposes. We aimed to determine
who among newly identiﬁed CRE rectal carriers is prone to have a subsequent clinical specimen with CRE. A matched case-control
study was conducted in a tertiary care teaching hospital in Israel. Cases with a primary positive CRE rectal test and subsequent CRE
clinical specimens were matched in a 1:2 ratio with CRE rectal carriers who did not develop subsequent CRE clinical specimens
(controls). Matching was based on calendar time of primary CRE isolation, whether the primary CRE isolation was £48 h or >48 h after
hospital admission, and time at risk to have a subsequent clinical specimen. Data were extracted from the patients’ medical records and
from the hospital’s computerized database. One hundred and thirty-two newly identiﬁed CRE rectal carriers (44 cases, 88 controls)
were included. The median time interval between screening and subsequent clinical specimens was 11 days (range, 3–27); 86% of the
clinical specimens were classiﬁed as true infections. Independent predictors of subsequent CRE clinical specimens were: admission to
the intensive care unit, having a central venous catheter, receipt of antibiotics, and diabetes mellitus. Identiﬁcation of the risk factors for
subsequent infections among CRE-colonized patients can be used to control modiﬁable risk factors and to direct empirical antimicrobial
therapy when necessary.
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Introduction
Carbapenem-resistant Enterobacteriaceae (CRE) are emerging
extremely drug-resistant pathogens [1]. Enteric strains that
harbour carbapenemases, which are plasmid-encoded
enzymes, show remarkable epidemic success and have been
associated with local, regional and intercontinental dissemina-
tion. Such strains consist primarily of Klebsiella pneumoniae
that produce the serine carbapenemase Klebsiella pneumo-
niae carbapenemase (KPC) or the metallo-beta-lactamases
VIM or NDM-1 [2,3]. These organisms are typically resistant
to nearly all available antimicrobial agents [4] and infections
by them are associated with an increased risk of mortality
[5–7]. Thus, the spread of CRE harbouring carbapenemases
is a clinical and public health problem.
Strict contact isolation and physical separation of carriers
from non-carriers are key components in containing CRE in
acute care hospitals [8]. Relying solely on clinical cultures will
not detect the majority of CRE carriers [9]; therefore, active
surveillance of patients at high risk of CRE carriage is strongly
recommended [4,10]. Sites of CRE carriage include the lower
gastrointestinal tract, the oropharynx, skin and urine [11].
The primary surveillance screening site, which has been advo-
cated by the US Centers for Disease Control and Prevention
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(CDC) and the European Society of Clinical Microbiology and
Infectious Diseases, is the stool or rectal swab [4,10]. Indeed,
several studies have demonstrated the role of active surveil-
lance in the control of CRE outbreaks [12,13].
While the implications of having a positive CRE surveillance
test are clear in terms of infection control strategy (i.e. asymp-
tomatic carriers should be cohorted with clinically infected
patients), the impact of detection of asymptomatic coloniza-
tion on subsequent infection is unclear. In this study we aimed
to determine who among newly identiﬁed CRE rectal carriers
is prone to have a subsequent clinical specimen with CRE.
Methods
Study setting, patient population and deﬁnitions
The Tel Aviv Sourasky Medical Centre is a 1200-bed tertiary
care teaching hospital in Tel Aviv, Israel. This hospital (like
many other Israeli hospitals) has had ongoing CRE outbreaks
since 2006 (mainly blaKPC producing K. pneumoniae ST258).
Cohorting with dedicated staff and strict contact isolation
precautions have been enforced for all CRE patients since
mid-2007. In addition, screening has been routinely per-
formed for all patients hospitalized in acute or chronic care
facilities in the past year and for contacts of newly identiﬁed
CRE patients [14]. Patients are not cohorted until positive
screening results are ﬁnalized.
The study population included patients who were identi-
ﬁed as CRE carriers by rectal screening tests and had not
had prior positive clinical cultures for CRE at the study hos-
pital. Exclusion criteria were age <18 years and afﬁliation to
the obstetrics and gynaecology unit. Data were extracted
from the hospital’s computerized administrative and labora-
tory data repositories.
Study design
A matched case-control study was performed. Cases
included all patients with a primary positive CRE rectal test
and a subsequent positive CRE clinical culture between 1
May 2007 and 30 April 2009. A clinical culture was deﬁned
as any culture other than stool or rectal swab; in case of
multiple subsequent CRE clinical cultures, the one most
proximal to the positive screening test was assessed. For
each case, matched controls were selected at a 1:2 ratio
from a pool of patients with a primary positive CRE rectal
test and no subsequent positive CRE clinical cultures. Match-
ing was based on (i) calendar time (month/year) of the pri-
mary positive CRE rectal test; (ii) whether detection of
primary CRE rectal carriage was upon admission or later
during hospital stay (£48 h or >48 h from hospital admis-
sion); and (iii) follow-up time, deﬁned as the time-at-risk to
develop positive clinical samples after the positive screening
test (i.e. controls had to have at least the same follow-up
time as their matched case and were censored when reach-
ing the same follow-up time as their matched case).
Data collection
Data were extracted from the patients’ medical records and
from a hospital computerized database according to a pre-
prepared questionnaire. Three possible predictors of subse-
quent positive CRE clinical specimens were measured as con-
tinuous variables: age, days in hospital in the 30 days before
screening, and days in hospital during the follow-up period.
The following possible predictors were measured as categori-
cal variables: sex, admission from a long-term care facility or
from another hospital, co-morbid conditions (diabetes mell-
itus (DM), cardiovascular, renal, lung or neurological disease,
malignancy, immunodeﬁciency, skin ulcers), debilitated func-
tional state, hospital unit at the time of screening, contact
with the healthcare system 30 days before screening (hospi-
talization ‡2 days, mechanical ventilation, exposure to antibi-
otics >1 day) and during the follow-up period (hospitalization
‡2 days and >7 days, admission to the intensive care unit
(ICU), mechanical ventilation, exposure to antibiotics (catego-
rized by class) >1 day, surgery, and presence of invasive
devices including permanent urinary catheter, central venous
catheter (CVC), enteral feeding tube, drain and endotracheal
tube). Two reviewers independently determined whether
CRE clinical specimens represented infection or colonization
based on deﬁnitions outlined by the CDC [15]; in cases of
disagreement, a third reviewer was consulted.
Microbiological methods
Rectal swabs were streaked onto selective MacConkey agar
plates supplemented with 1 mg/L imipenem. Growing colo-
nies were identiﬁed to the species level and tested for carba-
penem resistance using the Vitek 2 system (bioMerieux,
Marcy I’Etoile, France) and Etest for validation (AB Biodisk,
Solna, Sweden). This method has been determined to be
adequately sensitive (85%) and speciﬁc (94%) for screening
purposes [16]. Enterobacteriaceae colonies were also tested
for blaKPC using PCR. A CRE screening test was deﬁned as
positive if either a CRE isolate was identiﬁed and/or blaKPC
was detected. Clinical specimens were processed in accor-
dance with the CLSI guidelines [17] and isolates were identi-
ﬁed using the Vitek 2 system.
Statistical analysis
The association between presumptive predictors and subse-
quent CRE clinical specimens for the matched case-control
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triplets was ﬁrst examined by means of matched bivariate
analysis using stratiﬁed Cox regression with constant follow-
up time. Odds ratios (ORs) and their corresponding 95%
conﬁdence intervals (CIs) were calculated. Variables with a p
value of £0.10 were entered into a multivariate conditional
logistic regression analysis using Cox regression with con-
stant follow-up time. The ﬁnal model was constructed based
on a forward stepwise method with the likelihood ratio test,
in which variables with a p value £0.05 were retained. SPSS
statistics for Windows, PASW version 18.0, was used for
the analyses.
Results
Patient characteristics
Between 1 May 2007 and 30 April 2009 there were 502
newly identiﬁed CRE rectal carriers (out of 14 715 unique
specimens from 10 040 patients). Of these 502, 44 (8.8%)
developed subsequent positive clinical cultures with CRE;
these 44 were deﬁned as study cases. Among them, 12
patients were screened within 48 h of hospital admission and
32 were screened later during hospitalization. The time
interval between screening and subsequent clinical specimens
ranged from 3 to 27 days (mean 11 ± 7 days). Eighty-eight
newly identiﬁed CRE rectal carriers with no positive clinical
specimens for CRE who fulﬁlled matching criteria were ran-
domly selected as controls. Patients’ ages ranged from 26 to
101 years (mean 76 ± 13.6 years) and 52% were male.
Microbiological characteristics
Klebsiella pneumoniae was the predominant CRE isolate iden-
tiﬁed by rectal screening (43/44 cases (97.7%) and 79/88 con-
trols (89.8%)). Other CRE isolates included Escherichia coli
(n = 5), Enterobacter spp. (n = 2) and Citrobacter freundii
(n = 1), all among controls. Ninety-two per cent of the
tested CRE isolates were blaKPC positive. Two patients (one
case and one control) with no identiﬁed CRE isolate in their
screening specimen were categorized as CRE carriers
because of a positive PCR. K. pneumoniae was the only CRE
isolate identiﬁed in the subsequent clinical cultures. The anti-
microbial susceptibility proﬁle of the 174 CRE isolates is pre-
sented in Table 1. Susceptibility was low for all agents except
gentamicin and colistin.
Clinical characteristics
Among the 44 cases, 38 (86.4%) were classiﬁed as clinically
infected with CRE; types of infections included urinary tract
infection (n = 16, 42.1%), bloodstream infection (n = 8,
21.1%), pneumonia (n = 6, 15.8%), skin and soft tissue
infection including surgical site infection (n = 5, 13.2%), oste-
omyelitis including mastoiditis (n = 2, 5.2%), and intra-
abdominal infection (n = 1, 2.6%). The other six CRE clinical
cultures (four urine specimens, one penile discharge, and
one blood culture drawn from a CVC) were interpreted as
colonization.
Risk factor analysis
Table 2 presents the results of the bivariate analysis of risk
factors associated with having a subsequent CRE clinical
specimen. Cases were signiﬁcantly more likely than controls
to have a history of DM (43.2% vs. 26.1%, p 0.046). During
the month preceding the positive screening test, cases spent
fewer days in the hospital (12.7 vs. 17.1, p 0.007) and were
less likely to have been hospitalized for 2 or more days
(75.0% vs. 88.6%, p 0.026). During the follow-up period,
cases were more likely than controls to be hospitalized
longer (10.5 days vs. 8.8 days, p 0.095), to be admitted to
the ICU (11.4% vs. 2.3%, p 0.054), to have a CVC (20.5% vs.
6.8%, p 0.024), and to receive antibiotics (84.1% vs. 65.9%,
p 0.038). Investigation into the classes of antibiotics received
during that period revealed that there was signiﬁcantly
greater use of ﬂuoroquinolones and vancomycin among cases
than among controls (Table 3).
The multivariate analysis for matched data is presented in
Table 4. In this model, admission to the ICU, having a CVC,
and receipt of antibiotics (all during the follow-up period)
and DM were independent risk factors for subsequent clini-
cal CRE cultures. The variable ‘hospitalization in the month
preceding the screening test’ was not included in the ﬁnal
model because only 16% of study patients were classiﬁed as
not being hospitalized when the cut-off point was set at 2 or
more days; moreover, when different cut-off points were
used (7, 10, 14, and 21 days), there was no clear association
TABLE 1. Antimicrobial susceptibility proﬁle of 174 CRE isolatesa
AK GEN P/T CAZ CEF CIP LEVO T/S COL
Susceptibility ratesb (%) 28/174 (16.1) 148/174 (85.1) 0/174 (0.0) 0/174 (0.0) 2/174 (1.1) 5/174 (2.9) 13/174 (7.5) 13/174 (7.5) 39/39 (100)
aAll isolates were resistant to carbapenems by deﬁnition.
bNumber of susceptible isolates/number of isolates tested.
AK, amikacin; GEN, gentamicin; P/T, piperacillin/tazobactam; CAZ, ceftazidime; CEF, cefepime; CIP, ciproﬂoxacin; LEVO, levoﬂoxacin; T/S, trimethoprim-sulphamethoxazole;
COL, colistin.
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between this variable and the outcome measure. Substitution
of individual antibiotic classes for the covariate ‘antibiotics’
revealed that receipt of ﬂuoroquinolones was an indepen-
dent predictor of subsequent CRE clinical specimens.
Subgroup analysis of the 38 cases who were classiﬁed as
having a clinical infection with CRE and their matched con-
trols yielded similar results, except that metronidazole use
(in addition to ﬂuoroquinolone use) was also identiﬁed as an
independent risk factor for subsequent CRE clinical speci-
mens (OR, 3.04; 95% CI, 1.13–8.16; p 0.027).
Discussion
Colonization with potential pathogens is almost always a pre-
requisite for the development of nosocomial infections [18].
However, only a minority of colonized patients eventually
develops clinical infection [19,20]. This proportion is deter-
TABLE 3. Case-control comparison of antibiotic use by class
Antibiotic class
No. (%) of patients
OR (95% CI) p
Clinical
sample
No clinical
sample
Penicillins 14 (31.8) 18 (20.5) 1.81 (0.78–3.72) 0.178
Cephalosporins 13 (29.5) 26 (29.5) 1.00 (0.42–2.38) 1
b-lactam b-lactamase
inhibitor combinations
2 (4.5) 4 (4.5) 1.00 (0.16–6.42) 1
Carbapenems 6 (13.6) 11 (12.5) 1.10 (0.39–3.06) 0.860
Fluoroquinolones 15 (34.1) 12 (13.6) 3.68 (1.39–9.74) 0.009
Aminoglycosides 5 (11.4) 9 (10.2) 1.12 (0.36–3.49) 0.845
Vancomycin 11 (25.0) 9 (10.2) 2.78 (1.06–7.27) 0.037
Metronidazole 15 (34.1) 19 (21.6) 1.79 (0.83–3.89) 0.139
Colistin 5 (11.4) 6 (6.8) 1.67 (0.51–5.46) 0.399
Other antibiotic classes 7 (15.9) 13 (14.8) 1.10 (0.39–3.08) 0.860
TABLE 4. Multivariable analysis of risk factors associated
with subsequent clinical cultures with CRE
Variable OR (95% CI) p
ICU staya 7.45 (1.32–42.13) 0.023
Central venous cathetera 5.70 (1.39–23.39) 0.016
Receipt of antibioticsa 3.32 (1.14–9.69) 0.028
Receipt of a ﬂuoroquinolonea 3.04 (1.07–8.68) 0.037
Diabetes mellitus 2.79 (1.11–7.04) 0.030
ICU, intensive care unit.
aVariables refer to the follow-up period after the positive rectal screen test.
Omnibus test for both models (i.e. including the variable ‘antibiotics’ or ‘ﬂuor-
oquinolones’: p <0.01).
TABLE 2. Bivariate analysis of risk
factors associated with a positive
clinical specimen for CRE
Variable
Mean ± SD or n (%)
OR (95% CI) p
Clinical
sample
No clinical
sample
Demographic
Age (years) 75.9 ± 15.3 76.6 ± 12.8 0.780
Sex (male) 21 (47.7) 48 (54.5) 0.74 (0.34–1.60) 0.440
Institutiona 16 (37.2) 37 (48.1) 0.61 (0.27–1.40) 0.248
Admission unit (survey)
Non-internal medicine 9 (20.5) 15 (17.0) 1.30 (0.48–3.50) 0.608
ICU 3 (6.8) 1 (1.1) 6.00 (0.62–57.68) 0.121
Co-morbidities
Cardiovascular disease 35 (79.5) 67 (76.1) 1.23 (0.50–3.05) 0.652
Diabetes mellitus 19 (43.2) 23 (26.1) 2.29 (1.02–5.17) 0.046
Renal disease 15 (34.1) 19 (21.6) 2.04 (0.85–4.90) 0.110
Lung disease 10 (22.7) 19 (21.6) 1.07 (0.44–2.58) 0.880
Liver disease 3 (6.8) 3 (3.4) 2.38 (0.38–14.97) 0.355
Neurological disease 22 (50.0) 46 (52.3) 0.89 (0.40–2.00) 0.786
Malignant disease 9 (20.5) 16 (18.2) 1.15 (0.47–2.80) 0.758
Immunodeﬁciency 3 (6.8) 12 (13.6) 0.46 (0.12–1.73) 0.249
Decubitus ulcer 2 (4.5) 4 (4.5) 1.00 (0.16–6.42) 1.00
Debilitated functional status 28 (65.1) 44 (57.9) 1.38 (0.64–3.00) 0.408
Contact with the HCS before survey (30 days)
Any hospitalization (‡2 days) 33 (75.0) 78 (88.6) 0.09 (0.01–0.76) 0.026
Days in hospital 12.7 ± 10.7 17.1 ± 10.8 0.007
Ventilation 17 (38.6) 31 (35.2) 1.16 (0.55–2.48) 0.699
Receipt of antibiotics 35 (79.5) 67 (76.1) 1.22 (0.50–2.97) 0.659
Contact with the HCS after survey
Any hospitalization (‡2 days) 42 (95.5) 80 (90.9) 2.14 (0.43–10.71) 0.356
Days in hospital 10.5 ± 6.7 8.8 ± 6.2 0.095
Days in hospital >7 29 (65.9) 46 (52.3) 3.81 (1.03–14.02) 0.045
ICU stay 5 (11.4) 2 (2.3) 5.00 (0.97–25.77) 0.054
Ventilation 21 (47.7) 28 (31.8) 1.97 (0.92–4.20) 0.079
Receipt of antibiotics 37 (84.1) 58 (65.9) 2.69 (1.06–6.88) 0.038
Surgery 3 (6.8) 1 (1.1) 6.00 (0.62–57.68) 0.121
Instrumentation after survey
Urinary Foley catheter 26 (59.1) 42 (47.7) 1.52 (0.76–3.06) 0.241
Central venous catheter 9 (20.5) 6 (6.8) 4.65 (1.22–17.65) 0.024
Enteral feeding tube 7 (15.9) 19 (21.6) 0.66 (0.24–1.81) 0.420
Endotracheal tube 3 (6.8) 7 (8.0) 0.86 (0.22–3.32) 0.823
Drain 1 (2.3) 1 (1.1) NA
ICU, intensive care unit; HCS, healthcare system.
aAdmission from a long-term care facility or another hospital.
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mined by various factors, including pathogen virulence and
host defence mechanisms, medical procedures, and exposure
to antibiotics. Identiﬁcation of the risk factors for subsequent
infections among colonized patients is important; it may pro-
mote control of modiﬁable risk factors and can be used to
direct empirical antimicrobial therapy when necessary.
In this study we have addressed progression to infection
among patients with CRE rectal carriage. We used isolation
from clinical sites as a marker for infection and found that
8.8% of carriers later had a positive CRE clinical specimen, of
which most (86%) represented true infection. Our results
are very similar to a recently published study by Borer et al.,
also from Israel, in which 9% of carriers of carbapenem-resis-
tant K. pneumoniae developed clinical infection [21]. We
found the following variables to be predictors of CRE isola-
tion in clinical specimens among carriers: admission to the
ICU, having a CVC, exposure to antibiotics and DM.
ICU-acquired infections by multidrug-resistant bacteria are
important complications of the treatment of critically ill
patients [22]. Moreover, the ICU has been associated with
subsequent clinical infections among patients colonized with
drug-resistant bacteria, such as MRSA [19]. Suggested predis-
posing factors include: (i) patients’ underlying health impair-
ments; (ii) the acute disease process; (iii) the frequent use of
invasive devices; and (iv) the frequent use of broad-spectrum
antibiotics [22]. ICU stay and other indicators of severe ill-
ness, such as mechanical ventilation or APACHE score, have
also been identiﬁed as risk factors for CRE isolation [5,6,23–
26]. Our study clariﬁes the timing of the ICU stay in the
pathogenesis of CRE infection; namely, that once rectal colo-
nization has occurred, the ICU setting promotes the transi-
tion to clinical infection.
In addition to the role of the ICU, other ﬁndings in our
study suggest that the transition from CRE rectal carriage to
clinical infection is most likely to occur in the context of
acute illness. First, patients with subsequent CRE clinical cul-
tures had fewer days of hospitalization and a lower likeli-
hood of any hospitalization before screening. Second, the
time interval between screening and clinical specimen was
relatively short (<30 days in all cases and <14 days in 75% of
cases), indicating that as time passes, the risk of progression
from carriage to infection decreases.
Antibiotic pressure is an important determinant of the
development and spread of antibiotic-resistant bacteria [27] It
is also among the few modiﬁable risk factors for antibiotic
resistance. Data from previous studies have been very sup-
portive of the association between CRE colonization or infec-
tion and prior exposure to antibiotics; inconsistent deﬁnitions
of ‘prior’ and ‘exposure’ might explain at least some of the
discrepancy in results when speciﬁc antibiotic classes are con-
sidered [5,6,23–26,28–30]. In the present study we found that
the period after rectal carriage had been determined was the
time frame in which exposure to antibiotics increased the risk
of developing CRE infection. Regarding speciﬁc antibiotic clas-
ses, we identiﬁed exposure to ﬂuoroquinolones and to met-
ronidazole to be associated with subsequent CRE clinical
infection. The clinical implication of our ﬁndings is that antibi-
otic therapy, and speciﬁcally ﬂuoroquinolones and metronida-
zole, should be used with caution for CRE carriers.
Our study has several limitations. First, study subjects
were identiﬁed and classiﬁed based on microbiological data
solely from the study hospital. Second, clinical samples were
taken based on clinical judgement; it is possible that some
controls were misclassiﬁed because cultures were not taken,
which would bias the ORs toward the null hypothesis. Third,
patients might have acquired CRE at different time-points
before detection by the rectal screening test; therefore, the
period at risk in the study may not represent the entire per-
iod at risk. We believe that this bias is not important in our
study; if it existed, it would be relevant only to the minority
of patients who were screened upon hospital admission, and
not to the majority who were screened during hospitaliza-
tion (following contact with an index case). Fourth, the study
was conducted in Israel, a region with ongoing outbreaks of
KPC-producing CRE (mostly K. pneumoniae). The risk factors
identiﬁed in the present study are relevant to regions with
endemic/ongoing outbreaks of CRE harbouring blaKPC, but
may not be generalizable to other settings with different
resistance mechanisms. Other limitations of this study are its
retrospective nature and the relatively small sample size,
which might have prevented identiﬁcation of other predic-
tors of subsequent CRE clinical specimens, particularly
receipt of other antibiotic classes.
At a time when controlling the spread of CRE is becoming
increasingly complicated and mandates surveillance of high-
risk individuals, it is important to identify those carriers at
risk of developing clinical cultures with CRE. Attention to
antimicrobial stewardship could prevent the progression
from CRE carriage to infection.
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